Has Rachel Scott received payments from drug or device companies?

Yes. Drug and device makers reported $4,972 in general payments to Rachel Scott across 10 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rachel Scott did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rachel Scott come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rachel Scott

Obstetrics & Gynecology · Washington, DCNPI 1366753634

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,823 of the $4,972 with a category attached, or 97.0%. Viiv Healthcare Company accounts for 91.5% of it on its own, with 7 other manufacturers making up the rest. Among obstetrics & gynecology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,972in general payments, 2019–2025

Across 10 payments — averaging $497.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Viiv Healthcare Company$5K
Gilead$250
Amneal Pharmaceuticals LLC$46
Zydus Pharmaceuticals (USA) Inc.$34
AbbVie$23
Hikma Pharmaceuticals USA$23
plus $45 from 2 others

$701,106in research payments, 2019–2025

Across 72 payments — averaging $9737.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$263K
Gilead$229K
Viiv Healthcare Company$125K
Pfizer$56K
AbbVie$28K
Apotex Inc.$34
plus $93 from 4 others

What the payments were for

Consulting fees$4,82397%
Speaking & faculty fees$230%
Travel & lodging$932%
Food & beverage$331%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Viiv Healthcare Company	1	$4,550
Gilead	1	$250
Amneal Pharmaceuticals LLC	2	$46
Zydus Pharmaceuticals (USA) Inc.	2	$34
AbbVie	1	$23
Hikma Pharmaceuticals USA	1	$23
Merck	1	$23
Roche Diagnostics Corporation	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CABENUVA$4,550

How this compares

$4,972 in reported general payments places this provider in the 95th percentile of 195 obstetrics & gynecology providers in District of Columbia.

See all obstetrics & gynecology providers in District of Columbia →

Other obstetrics & gynecology in Washington

Mark HathawayWashington$180K
Renuka Darolia AdelizziWashington$72K
Jovana TavcarWashington$5K
Jamila PerrittWashington$5K
Stephanie HackWashington$4K
Nicholas HazenWashington$4K
Serina FloydWashington$4K
Amr MadkourWashington$4K
Peng YeWashington$3K
Sarah SwartzWashington$3K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →